The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant atezolizumab plus docetaxel/oxaliplatin/capecitabine in non-metastatic gastric and gastroesophageal junction adenocarcinoma: The PANDA trial.
 
Yara L. Verschoor
No Relationships to Disclose
 
Liudmila Kodach
No Relationships to Disclose
 
José van den Berg
No Relationships to Disclose
 
Johanna W. van Sandick
No Relationships to Disclose
 
Jolanda van Dieren
No Relationships to Disclose
 
Sara Balduzzi
No Relationships to Disclose
 
Cecile Grootscholten
No Relationships to Disclose
 
Xander Veenhof
No Relationships to Disclose
 
Koen Hartemink
No Relationships to Disclose
 
Marieke A. Vollebergh
No Relationships to Disclose
 
E.C. Owers
No Relationships to Disclose
 
Annemarieke Bartels-Rutten
No Relationships to Disclose
 
Peggy den Hartog
No Relationships to Disclose
 
Monique E van Leerdam
No Relationships to Disclose
 
Ton Schumacher
Consulting or Advisory Role - Allogene Therapeutics; Asher Biotherapeutics; Merus NV; Neogene Therapeutics; Scenic Biotech
Patents, Royalties, Other Intellectual Property - IP related to the CD47 immune checkpoint, licensed by Scenic Biotech
 
Emile E. Voest
Consulting or Advisory Role - Aglaia BioMedical Ventures (Inst); Biogeneration Ventures; InteRNA; Life Sciences Partners (Inst); Roche Pharma AG (Inst); Servier (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); POEM Health (Inst); Roche/Genentech (Inst); Sanofi (Inst); T-Knife (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Myriam Chalabi
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)